Unscripted the AMCP Podcast: Alopecia Areata: New Guidelines, New Treatments, and a New Standard ...

On this episode guest host Steve Kheloussi, PharmD, MBA, FAMCP, welcomes returning guest Dr. Arash Mostaghimi, MD, MPA, MPH, Associate Professor of Dermatology at Harvard Medical School and Vice Chair of Clinical Trials and Innovation and Director of the Dermatology Inpatient Service at Brigham and Women’s Hospital, to discuss the rapidly evolving treatment landscape for alopecia areata. Once a condition with no FDA-approved therapies, alopecia areata now has three approved JAK inhibitors—with a fourth potentially on the horizon—and new clinical guidelines that may reshape how disease severity is defined and treated. Dr. Mostaghimi explains why traditional measures such as SALT scores may not fully capture the burden of disease, how the new AASC framework incorporates psychosocial impact, and what these changes could mean for coverage decisions, step therapy requirements, and formulary management. Find all of our network podcasts on your favorite podcast platforms and be sure to subscribe and like us. Learn more at www.healthcarenowradio.com/listen